UNITÉ DE FABRICATION DES MÉDICAMENTS S.A |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.09 TND | 0.00% |
|
-2.74% | -5.21% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 * | 134M 43.15M 3.6B | Sales 2024 * | 141M 45.4M 3.79B | Capitalization | 227M 73.06M 6.1B |
|---|---|---|---|---|---|
| Net income 2023 * | 16M 5.15M 430M | Net income 2024 * | 18M 5.8M 484M | EV / Sales 2023 * | 2.15 x |
| Net Debt 2023 * | 61.1M 19.67M 1.64B | Net Debt 2024 * | 66.6M 21.45M 1.79B | EV / Sales 2024 * | 2.08 x |
| P/E ratio 2023 * |
12.2
x | P/E ratio 2024 * |
11.4
x | Employees | 572 |
| Yield 2023 * |
7.05% | Yield 2024 * |
7.76% | Free-Float | 29.98% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -2.74% | ||
| Current month | -1.53% | ||
| 1 month | -1.39% | ||
| 3 months | -0.70% | ||
| 6 months | -3.41% | ||
| Current year | -5.21% |
1 week
7.05
7.25
1 month
7.057.35
Current year
6.927.56
1 year
6.858.28
3 years
6.618.28
5 years
6.6110.95
10 years
6.6111.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/89/01 | |
| Director of Finance/CFO | - | - | |
Imen Charfeddine
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/89/01 | |
| Director of Finance/CFO | - | - | |
Salah Ben Turkia
BRD | Director/Board Member | - | 01/16/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 7.09 | 0.00% | 3,023 |
| 14/24/14 | 7.09 | -0.14% | 1,123 |
| 13/24/13 | 7.1 | -1.93% | 5,570 |
| 10/24/10 | 7.24 | -0.41% | 7,419 |
| 09/24/09 | 7.27 | -0.27% | 420 |
End-of-day quote Tunis, May 15, 2024
More quotes
Unimed (Unité de Fabrication de Médicaments) is one of the leading pharmaceutical groups in Tunisia. The activity is organized around 2 families of products:
- generic medicines: primarily infusion and inhalation products, ophthalmic products, injectable liquids and powders;
- fashioned medicines: medicines manufactured for third parties.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.09
TND
Average target price
11.9
TND
Spread / Average Target
+67.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.21% | 72.64M | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- UMED Stock
